Skip to main content
Top
Published in: Annals of Nuclear Medicine 1/2023

01-11-2022 | Radioiodine Therapy | Original Article

Outcome of patients with differentiated thyroid cancer treated with empirical radioiodine therapy on the basis of Thyroglobulin Elevation Negative Iodine Scintigraphy (TENIS) syndrome without structural disease: a retrospective cohort study

Authors: Liyi Yuan, Jing Wang, Liqin Pan, Huijuan Feng, Pan Chen, Jiaxin Luo, Jiahao Xie, Xiaoli Xiong, Juqing Wu, Wei Ouyang

Published in: Annals of Nuclear Medicine | Issue 1/2023

Login to get access

Abstract

Background

For differentiated thyroid cancer (DTC) patients with thyroglobulin (Tg) elevation and negative iodine scintigraphy (commonly termed "TENIS" syndrome) after thyroidectomy, radioactive iodine (RAI) therapy, and thyroid-stimulating hormone (TSH) suppression therapy, empirical RAI therapy may be considered. However, the outcome data of TENIS syndrome without structural disease after empirical RAI therapy have not shown clear evidence of improvement in survival. We assessed the efficacy of such empirical RAI therapy in TENIS syndrome without structural disease and evaluated the progression-free survival (PFS).

Methods

A total of 80 papillary thyroid cancer (PTC) patients with TENIS syndrome without structural disease were included in this retrospective study. 52 patients were treated with empirical RAI therapy while another 28 patients were untreated. The progression-free survival (PFS) of both groups was defined as the main outcome. The secondary outcome was the comparison of serum Tg levels 12 months after being diagnosed as TENIS syndrome.

Results

The PFS of the empirical RAI therapy group was better than the untreated group (p < 0.001). Moreover, there was significant difference in Tg normalization between patients treated with empirical therapy and without treatment (p = 0.001). Empirical RAI therapy (p = 0.001) predicts better PFS. Male gender (p = 0.041) and empirical RAI therapy (p = 0.002) predict better remission in serum Tg level.

Conclusion

Patients with TENIS syndrome without structural disease can benefit from empirical RAI therapy in both PFS and Tg normalization.
Literature
1.
go back to reference Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.CrossRef Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.CrossRef
2.
go back to reference Klain M, Pace L, Zampella E, et al. Outcome of patients with differentiated thyroid cancer treated with 131-iodine on the basis of a detectable serum thyroglobulin level after initial treatment. Front Endocrinol (Lausanne). 2019;10:146.CrossRef Klain M, Pace L, Zampella E, et al. Outcome of patients with differentiated thyroid cancer treated with 131-iodine on the basis of a detectable serum thyroglobulin level after initial treatment. Front Endocrinol (Lausanne). 2019;10:146.CrossRef
3.
go back to reference Basu S, Dandekar M, Joshi A, et al. Defining a rational step-care algorithm for managing thyroid carcinoma patients with elevated thyroglobulin and negative on radioiodine scintigraphy (TENIS): considerations and challenges towards developing an appropriate roadmap. Eur J Nucl Med Mol Imaging. 2015;42:1167–71.CrossRef Basu S, Dandekar M, Joshi A, et al. Defining a rational step-care algorithm for managing thyroid carcinoma patients with elevated thyroglobulin and negative on radioiodine scintigraphy (TENIS): considerations and challenges towards developing an appropriate roadmap. Eur J Nucl Med Mol Imaging. 2015;42:1167–71.CrossRef
4.
go back to reference Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133.CrossRef Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133.CrossRef
5.
go back to reference Kabasakal L, Selcuk NA, Shafipour H, et al. Treatment of iodine-negative thyroglobulin-positive thyroid cancer: differences in outcome in patients with macrometastases and patients with micrometastases. Eur J Nucl Med Mol Imaging. 2004;31:1500–4.CrossRef Kabasakal L, Selcuk NA, Shafipour H, et al. Treatment of iodine-negative thyroglobulin-positive thyroid cancer: differences in outcome in patients with macrometastases and patients with micrometastases. Eur J Nucl Med Mol Imaging. 2004;31:1500–4.CrossRef
6.
go back to reference Sabra MM, Grewal RK, Tala H, et al. Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans. Thyroid. 2012;22:877–83.CrossRef Sabra MM, Grewal RK, Tala H, et al. Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans. Thyroid. 2012;22:877–83.CrossRef
7.
go back to reference Tramontin MY, Nobre GM, Lopes M, et al. High thyroglobulin and negative whole-body scan: no long-term benefit of empiric radioiodine therapy. Endocrine. 2021;73:398–406.CrossRef Tramontin MY, Nobre GM, Lopes M, et al. High thyroglobulin and negative whole-body scan: no long-term benefit of empiric radioiodine therapy. Endocrine. 2021;73:398–406.CrossRef
8.
go back to reference Gianoukakis AG. Thyroglobulin antibody status and differentiated thyroid cancer: what does it mean for prognosis and surveillance? Curr Opin Oncol. 2015;27:26–32.CrossRef Gianoukakis AG. Thyroglobulin antibody status and differentiated thyroid cancer: what does it mean for prognosis and surveillance? Curr Opin Oncol. 2015;27:26–32.CrossRef
9.
go back to reference Suteau V, Munier M, Briet C, et al. Sex bias in differentiated thyroid cancer. Int J Mol Sci. 2021;22(23):12992.CrossRef Suteau V, Munier M, Briet C, et al. Sex bias in differentiated thyroid cancer. Int J Mol Sci. 2021;22(23):12992.CrossRef
10.
go back to reference Preissner CM, O’Kane DJ, Singh RJ, et al. Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assays. J Clin Endocrinol Metab. 2003;88:3069–74.CrossRef Preissner CM, O’Kane DJ, Singh RJ, et al. Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assays. J Clin Endocrinol Metab. 2003;88:3069–74.CrossRef
11.
go back to reference Cheng L, Sa R, Luo Q, et al. Unexplained hyperthyroglobulinemia in differentiated thyroid cancer patients as an indication for radioiodine adjuvant therapy: a prospective multicenter study. J Nucl Med. 2021;62:62–8.CrossRef Cheng L, Sa R, Luo Q, et al. Unexplained hyperthyroglobulinemia in differentiated thyroid cancer patients as an indication for radioiodine adjuvant therapy: a prospective multicenter study. J Nucl Med. 2021;62:62–8.CrossRef
12.
go back to reference Shinohara S, Kikuchi M, Suehiro A, et al. Characteristics and prognosis of patients with thyroglobulin-positive and radioactive iodine whole-body scan-negative differentiated thyroid carcinoma. Jpn J Clin Oncol. 2015;45:427–32.CrossRef Shinohara S, Kikuchi M, Suehiro A, et al. Characteristics and prognosis of patients with thyroglobulin-positive and radioactive iodine whole-body scan-negative differentiated thyroid carcinoma. Jpn J Clin Oncol. 2015;45:427–32.CrossRef
13.
go back to reference Kim WG, Ryu JS, Kim EY, et al. Empiric high-dose 131-iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18F-fluorodeoxyglucose positron emission tomography scan. J Clin Endocrinol Metab. 2010;95:1169–73.CrossRef Kim WG, Ryu JS, Kim EY, et al. Empiric high-dose 131-iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18F-fluorodeoxyglucose positron emission tomography scan. J Clin Endocrinol Metab. 2010;95:1169–73.CrossRef
14.
go back to reference Carrillo JF, Vazquez-Romo R, Ramirez-Ortega MC, et al. Prognostic impact of direct (131)I therapy after detection of biochemical recurrence in intermediate or high-risk differentiated thyroid cancer: a retrospective cohort study. Front Endocrinol (Lausanne). 2019;10:737.CrossRef Carrillo JF, Vazquez-Romo R, Ramirez-Ortega MC, et al. Prognostic impact of direct (131)I therapy after detection of biochemical recurrence in intermediate or high-risk differentiated thyroid cancer: a retrospective cohort study. Front Endocrinol (Lausanne). 2019;10:737.CrossRef
15.
go back to reference Rosario PW, Mourao GF, dos Santos JB, et al. Is empirical radioactive iodine therapy still a valid approach to patients with thyroid cancer and elevated thyroglobulin? Thyroid. 2014;24:533–6.CrossRef Rosario PW, Mourao GF, dos Santos JB, et al. Is empirical radioactive iodine therapy still a valid approach to patients with thyroid cancer and elevated thyroglobulin? Thyroid. 2014;24:533–6.CrossRef
16.
go back to reference Fatourechi V, Hay ID, Javedan H, et al. Lack of impact of radioiodine therapy in tg-positive, diagnostic whole-body scan-negative patients with follicular cell-derived thyroid cancer. J Clin Endocrinol Metab. 2002;87:1521–6.CrossRef Fatourechi V, Hay ID, Javedan H, et al. Lack of impact of radioiodine therapy in tg-positive, diagnostic whole-body scan-negative patients with follicular cell-derived thyroid cancer. J Clin Endocrinol Metab. 2002;87:1521–6.CrossRef
17.
go back to reference Wang H, Dai H, Li Q, et al. Investigating (18)F-FDG PET/CT parameters as prognostic markers for differentiated thyroid cancer: a systematic review. Front Oncol. 2021;11: 648658.CrossRef Wang H, Dai H, Li Q, et al. Investigating (18)F-FDG PET/CT parameters as prognostic markers for differentiated thyroid cancer: a systematic review. Front Oncol. 2021;11: 648658.CrossRef
18.
go back to reference Liu M, Cheng L, Jin Y, et al. Predicting I-avidity of metastases from differentiated thyroid cancer using F-FDG PET/CT in postoperative patients with elevated thyroglobulin. Sci Rep. 2018;8:4352.CrossRef Liu M, Cheng L, Jin Y, et al. Predicting I-avidity of metastases from differentiated thyroid cancer using F-FDG PET/CT in postoperative patients with elevated thyroglobulin. Sci Rep. 2018;8:4352.CrossRef
19.
go back to reference Salvatore B, Klain M, Nicolai E, et al. Prognostic role of FDG PET/CT in patients with differentiated thyroid cancer treated with 131-iodine empiric therapy. Medicine (Baltimore). 2017;96: e8344.CrossRef Salvatore B, Klain M, Nicolai E, et al. Prognostic role of FDG PET/CT in patients with differentiated thyroid cancer treated with 131-iodine empiric therapy. Medicine (Baltimore). 2017;96: e8344.CrossRef
20.
go back to reference Stangierski A, Kaznowski J, Wolinski K, et al. The usefulness of fluorine-18 fluorodeoxyglucose PET in the detection of recurrence in patients with differentiated thyroid cancer with elevated thyroglobulin and negative radioiodine whole-body scan. Nucl Med Commun. 2016;37:935–8.CrossRef Stangierski A, Kaznowski J, Wolinski K, et al. The usefulness of fluorine-18 fluorodeoxyglucose PET in the detection of recurrence in patients with differentiated thyroid cancer with elevated thyroglobulin and negative radioiodine whole-body scan. Nucl Med Commun. 2016;37:935–8.CrossRef
Metadata
Title
Outcome of patients with differentiated thyroid cancer treated with empirical radioiodine therapy on the basis of Thyroglobulin Elevation Negative Iodine Scintigraphy (TENIS) syndrome without structural disease: a retrospective cohort study
Authors
Liyi Yuan
Jing Wang
Liqin Pan
Huijuan Feng
Pan Chen
Jiaxin Luo
Jiahao Xie
Xiaoli Xiong
Juqing Wu
Wei Ouyang
Publication date
01-11-2022
Publisher
Springer Nature Singapore
Published in
Annals of Nuclear Medicine / Issue 1/2023
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-022-01799-5

Other articles of this Issue 1/2023

Annals of Nuclear Medicine 1/2023 Go to the issue